Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Sell
44
OPHLY Quote, Financials, Valuation and Earnings
Last price:
$3.60
Seasonality move
:
1.1%
Day range:
$3.67 - $3.71
52-week range:
$3.21 - $5.20
Dividend yield:
4.87%
P/E ratio:
15.56x
P/S ratio:
1.61x
P/B ratio:
1.00x
Volume:
245.9K
Avg. volume:
244K
1-year change:
-20.77%
Market cap:
$5.2B
Revenue:
$3.2B
EPS (TTM):
$0.24
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Ono Pharmaceutical has -- downside to fair value with a price target of -- per share.
OPHLY vs. S&P 500
-
Over the past 5 trading days, Ono Pharmaceutical has overperformed the S&P 500 by 3.87% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ono Pharmaceutical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ono Pharmaceutical has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Ono Pharmaceutical reported revenues of $880M.
Earnings Growth
-
Ono Pharmaceutical earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Ono Pharmaceutical reported earnings per share of $0.07.
Enterprise value:
4.7B
EV / Invested capital:
--
Price / LTM sales:
1.61x
EV / EBIT:
10.94x
EV / Revenue:
1.47x
PEG ratio (5yr expected):
22.52x
EV / Free cash flow:
7.79x
Price / Operating cash flow:
11.25x
Enterprise value / EBITDA:
7.76x
Gross Profit (TTM):
$2.3B
Return On Assets:
4.65%
Net Income Margin (TTM):
10.37%
Return On Equity:
6.28%
Return On Invested Capital:
5.27%
Operating Margin:
11.08%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $3.3B | $3.5B | $3.5B | $888.5M | $880M | |
| Gross Profit | $2.4B | $2.7B | $2.5B | $680.6M | $579.5M | |
| Operating Income | $1.1B | $1.2B | $908.5M | $322.3M | $97.5M | |
| EBITDA | $1.2B | $1.3B | $1.1B | $362M | $169.8M | |
| Diluted EPS | $0.57 | $0.62 | $0.53 | $0.17 | $0.07 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.2B | $2.3B | $2.6B | $2.7B | $3B | |
| Total Assets | $6.8B | $6.1B | $6.6B | $6B | $7.1B | |
| Current Liabilities | $849.7M | $540.1M | $922.6M | $684.6M | $991.1M | |
| Total Liabilities | $958M | $635.2M | $1B | $760.2M | $1.8B | |
| Total Equity | $5.8B | $5.4B | $5.6B | $5.3B | $5.3B | |
| Total Debt | -- | -- | -- | -- | $902.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2023-03-31 | 2024-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $550.7M | $1.2B | $766.9M | $365.8M | $350.4M | |
| Cash From Investing | $53.8M | -$742.5M | $333.2M | -$424.3M | $202M | |
| Cash From Financing | -$536.6M | -$240.6M | -$622.6M | -$21.6M | -$112.3M | |
| Free Cash Flow | $441.4M | $1.1B | $622.5M | $329.7M | $275.7M | |
OPHLY
Sector
Market Cap
$5.2B
$34.4M
Price % of 52-Week High
71.15%
48.88%
Dividend Yield
4.87%
0%
Shareholder Yield
9.23%
-1.01%
1-Year Price Total Return
-20.77%
-37.36%
Beta (5-Year)
0.366
0.614
Dividend yield:
4.87%
Annualized payout:
$0.18
Payout ratio:
--
Growth streak:
3 years
Technicals
8-day SMA
Buy
Level
$3.59
200-day SMA
Sell
Level
$3.71
Bollinger Bands (100)
Buy
Level
3.45 - 3.81
Chaikin Money Flow
Sell
Level
-5.6K
20-day SMA
Buy
Level
$3.55
Relative Strength Index (RSI14)
Buy
Level
62.54
ADX Line
Buy
Level
18.34
Williams %R
Sell
Level
-3.3333
50-day SMA
Buy
Level
$3.53
MACD (12, 26)
Buy
Level
0.99
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
1.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.6525)
Buy
CA Score
(Annual)
Level (1.3764)
Buy
Beneish M-Score
(Annual)
Level (-2.9669)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-1.7735)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a world-wide business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.
Stock Forecast FAQ
In the current month, OPHLY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OPHLY average analyst price target in the past 3 months is --.
-
Where Will Ono Pharmaceutical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ono Pharmaceutical share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Ono Pharmaceutical?
Analysts are divided on their view about Ono Pharmaceutical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ono Pharmaceutical is a Sell and believe this share price will rise from its current level to --.
-
What Is Ono Pharmaceutical's Price Target?
The price target for Ono Pharmaceutical over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OPHLY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ono Pharmaceutical is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of OPHLY?
You can purchase shares of Ono Pharmaceutical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ono Pharmaceutical shares.
-
What Is The Ono Pharmaceutical Share Price Today?
Ono Pharmaceutical was last trading at $3.60 per share. This represents the most recent stock quote for Ono Pharmaceutical. Yesterday, Ono Pharmaceutical closed at $3.70 per share.
-
How To Buy Ono Pharmaceutical Stock Online?
In order to purchase Ono Pharmaceutical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 13.4% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.56% over the past day.
Sell
42
VLCN alert for Jul 17
Volcon [VLCN] is up 194.76% over the past day.
